In a data-driven world, pauses in government economic data do more than inconvenience economists, they create dangerous blind spots for investors and business leaders.
Objectives To describe the features and rates of emergency department (ED) presentations identified as related to violence against women (VAW) and of confirmed cases of family domestic violence (FDV) ...
JADE101 is an investigational,potentially best-in-class disease-modifyinganti-APRIL monoclonal antibody, with a Phase 1 healthy volunteer study underway SAN FRANCISCO and VANCOUVER, British Columbia, ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the ...
STOWE TOWNSHIP, Pa. — Commissioners in Stowe Township will hear from SunCap Industries, the owner of property that could soon house a data center. It’s the site of the former Pressed Steel Car Company ...
THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 ...
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, ...
30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data ...
WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
Abstract: Deep neural networks (DNNs) are sensitive to adversarial examples which are generated by corrupting benign examples with imperceptible perturbations, or have significant changes but can ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results